Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Efalizumab | |
| Synonyms |
EFALIZUMAB Efalizumab Hu 1124 Raptiva Xanelim efalizumab |
|
| Definitions |
A humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. Efalizumab binds to CD11a, which is expressed on all leukocytes, resulting in a reduction in the cell surface expression of CD11a. In addition, this agent inhibits the binding of LFA-1 to intercellular adhesion molecule-1 (ICAM-1), resulting in the inhibition of leukocyte adherence and the suppression of cell-mediated immunity. LFA-1 binding to ICAM-1 is involved in the activation of T lymphocytes, adhesion of T lymphocytes to endothelial cells, and migration of T lymphocytes to sites of inflammation. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C68831 |
|
| ALT_DEFINITION |
A monoclonal antibody used to treat psoriasis (a chronic skin disease). It is also being studied in the treatment of graft-versus-host disease (GVHD) of the skin after a donor stem cell transplant. Efalizumab binds to a molecule called LFA-1, and blocks the action of T cells (a type of white blood cell). It is a type of immunosuppressant.
|
|
| CAS_Registry |
214745-43-4
|
|
| code |
C68831
|
|
| Concept_In_Subset | ||
| Contributing_Source |
FDA
|
|
| DEFINITION |
A humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. Efalizumab binds to CD11a, which is expressed on all leukocytes, resulting in a reduction in the cell surface expression of CD11a. In addition, this agent inhibits the binding of LFA-1 to intercellular adhesion molecule-1 (ICAM-1), resulting in the inhibition of leukocyte adherence and the suppression of cell-mediated immunity. LFA-1 binding to ICAM-1 is involved in the activation of T lymphocytes, adhesion of T lymphocytes to endothelial cells, and migration of T lymphocytes to sites of inflammation.
|
|
| FDA_UNII_Code |
XX2MN88N5D
|
|
| FULL_SYN |
EFALIZUMAB Efalizumab Hu 1124 Raptiva Xanelim efalizumab
|
|
| label |
Efalizumab
|
|
| Legacy Concept Name |
Efalizumab
|
|
| NCI_Drug_Dictionary_ID |
553413
|
|
| PDQ_Closed_Trial_Search_ID |
553413
|
|
| PDQ_Open_Trial_Search_ID |
553413
|
|
| Preferred_Name |
Efalizumab
|
|
| prefixIRI |
Thesaurus:C68831
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C1320125
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |